The Impact of Covid-19 on the Pharmaceutical Industry of Pakistan; An analysis of the variation in the share prices pre and post Covid

Abstract

The project "Impact of Covid-19 on the pharmaceutical industry of Pakistan; an analysis of the variation in the share prices before and after Covid-19" seeks to learn more about the effects of the worldwide pandemic on Pakistan's pharmaceutical sector while concentrating on share price changes. In order to establish a direct correlation between these variables, this project investigates the relationship between key financial indicators, such as net profit margin, earnings per share, and current ratio, and share price returns. In order to meet the project's goals, a thorough analysis of Pakistan's pharmaceutical sector was carried out, looking at share price changes of a few chosen companies before and after the Covid-19 pandemic. Data on the pre- and post-pandemic periods' pre-pandemic net profit margins, earnings per share, current ratios, and share price returns were gathered for a given time frame. To determine the strength and direction of the relationships between Net profit margin, earnings per share, current ratio, and share price returns, the study used statistical techniques like regression analysis. The project's analysis of the data sought to find any appreciable relationships between these financial indicators and share price increases, highlighting the effect of Covid-19 on the pharmaceutical sector. The results of this study will help us comprehend the dynamics of Pakistan's pharmaceutical sector more fully during the Covid-19 pandemic. The project will also provide important insights for investors, industry stakeholders, and policymakers regarding the connection between financial performance indicators and share price returns This project aims to show the impact of financial performance on the valuation of pharmaceutical companies in Pakistan by establishing a direct correlation between net profit margin, earnings per share, current ratio, and share price returns. The findings will serve as a foundation for upcoming pharmaceutical industry research and decision-making procedures, assisting stakeholders in navigating the difficulties presented by the ongoing pandemic and other market uncertainties.